PPARγ blocks carcinogenesis and the invasive and metastatic potentials of HCC [23], [24], indicating that the application of PPARγ agonists may be a therapeutic prospect for HCC treatment. This evidence concerns the gene PPARG and hepatocellular carcinoma.